The relationship between third-generation TSH receptor antibody positivity and cumulative methimazole dose used until remission in graves' disease
Journal of the College of Physicians and Surgeons Pakistan, vol.31, no.5, pp.517-522, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 31 Issue: 5
- Publication Date: 2021
- Doi Number: 10.29271/jcpsp.2021.05.517
- Journal Name: Journal of the College of Physicians and Surgeons Pakistan
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
- Page Numbers: pp.517-522
- Keywords: Graves' disease, TSH receptor antibody, Cumulative, Methimazole
- Open Archive Collection: AVESIS Open Access Collection
- Kütahya Health Sciences University Affiliated: No
Abstract
© 2021 College of Physicians and Surgeons Pakistan. All rights reserved.Objective: To determine the relationship between the positivity of third-generation TSH receptor antibody (TRAb) at the time of diagnosis and the cumulative methimazole dose used until remission in patients with Graves’ disease. Study Design: Cross-sectional, descriptive study. Place and Duration of Study: Department of Endocrinology and Metabolic Diseases, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Turkey from 2016 to 2018. Methodology: Newly diagnosed Graves' patients were included in the study. The patients were divided into two groups according to whether they entered remission (n: 21) or not (n: 20), in the 18th month of methimazole treatment. In addition, the patients were further divided into two categories, according to TRAb status at the time of diagnosis as negative (n: 17) or positive (n: 24). The TRAb positivity and the cumulative methimazole dose they used until the month of remission were compared in these groups. Results: The mean time to reach remission in 41 patients was 20.5 ± 3.1 months. TSH receptor antibody positivity rate was 58.5%. When the TRAb positivity of the groups was compared according to the state of having remission in the 18th month of the treatment, the positivity rate in the non-remission group was statistically significantly higher (p = 0.023).The time to go into remission was longer and the cumulative methimazole dose requirement was higher in the TRAb positive group (p <0.001). Conclusion: Graves’ disease patients with positive third-generation TRAb were found to have a lower rate of remission in the 18-month period compared to negative patients.